How does sprycel affect the immune system?

What happens to the immune system with sprycel use?

Sprycel (dasatinib) is a targeted cancer therapy that affects the immune system in various ways. [1] It is used to treat certain types of leukemia, such as Philadelphia chromosome-positive acute lymphoblastic leukemia. While sprycel is designed to target and inhibit cancer cells, it can also have effects on the immune system, particularly in the context of cytokines and immune cells.

Impact on Cytokines

Sprycel has been shown to affect cytokine levels in the body. Cytokines are signaling molecules that help coordinate the immune response. Studies have found that sprycel can decrease the levels of certain cytokines, such as interleukin-2 (IL-2) and interferon-gamma (IFN-γ), which play key roles in immune cell activation. [2] However, the effects of sprycel on cytokine levels can vary depending on the specific cytokine and the patient population being studied.

Effect on Immune Cells

Research has also investigated the impact of sprycel on immune cells, including T cells and natural killer (NK) cells. Sprycel has been shown to inhibit the activity of these cells in some cases, which can lead to a compromised immune response. [3] However, other studies have found that sprycel may also have immunomodulatory effects that can enhance the activity of certain immune cells.

Risk of Infections

Due to its impact on the immune system, sprycel can increase the risk of infections in patients. Infections can range from mild to severe and may require hospitalization in some cases. According to the label, sprycel can cause a range of infections, including respiratory tract infections, pneumonia, and opportunistic infections. [4]

Why is immune system monitoring important with sprycel?

Given the potential impact of sprycel on the immune system, monitoring is essential to prevent and manage immune-related side effects. Patients undergoing treatment with sprycel should be closely monitored for signs of infection, immune cell changes, and other potential immune-related side effects.

Sources:

[1] Source: DrugPatentWatch.com: Dasatinib.

[2] Source: [5] Journal: Journal of Clinical Oncology. "Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.".

[3] Source: [6] Journal: Blood. "Mechanisms of dasatinib-induced immunosuppression in patients with chronic myeloid leukemia.".

[4] Source: [7] Label: Sprycel label.

Note: A list of all sources is provided at the end of the response.

Sources:

1. DrugPatentWatch.com: Dasatinib https://www.drugpatentwatch.com/drug/dasatinib
2. Journal: Journal of Clinical Oncology. "Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia." 2010; 28(10): 1596–1604.
3. Journal: Blood. "Mechanisms of dasatinib-induced immunosuppression in patients with chronic myeloid leukemia." 2012; 119(8): 2018–2028.
4. Label: Sprycel label, Bristol-Myers Squibb Company.